close
Add to watchlist
Anadys Pharmaceuticals Inc (ANDS) Healthcare, Biotechnology & Drugs
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for the treatment of hepatitis C and cancer. The company was formerly known as Scriptgen Pharmaceuticals, Inc. and changed its name to Anadys Pharmaceuticals, Inc. in May 2000. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.70 |
| Volume | 0 |
| Volume Avg | (mio) 1.79 |
| 52 Week High | 3.70 |
| 52 Week Low | 0.60 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.45 |
| EPS change Q/Q | -150% |
| EPS change Q/Q Yr ago | -41.18% |
| EPS change Q/Q next Q est | -28.57% |
| EPS change Y/Y | -112.12% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.14 |
| EPS next Y est | -0.46 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |